The Chengdu system for recurrent hepatocellular carcinoma: A step in the right direction.

Liver cancer is the fourth leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC), the most prevalent cause of primary liver cancer, is observed highest in the Far East, South-Eastern Asia and East Africa (1). In most endemic regions this is secondary to the prevalence of specific risk factors including chronic hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and aflatoxin-exposure (1,2). The development of HBV vaccination and programmes to reduce HBV transmission has reduced the risk of HCC in high-risk Asian countries (1). Global incidence of HCC however continues to rise and major contributory factors to this are alcohol misuse and the obesity epidemic, resulting in non-alcoholic fatty liver disease, in Western nations (1,2).

[1]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[2]  S. Du,et al.  Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. , 2018, Hepatobiliary surgery and nutrition.

[3]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[4]  Yaming Li,et al.  Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) , 2018, Liver Cancer.

[5]  A. Darzi,et al.  Meta‐analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma , 2017, The British journal of surgery.

[6]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[7]  J. Rowe,et al.  Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis , 2017, Journal of carcinogenesis.

[8]  M. Makuuchi,et al.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Oncology.

[9]  J. Lee,et al.  Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. , 2015, Gastroenterology.

[10]  P. Ziakas,et al.  Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. , 2015, World journal of hepatology.

[11]  Michael Crawford,et al.  Preoperative assessment of postoperative liver function: The importance of residual liver volume , 2014, Journal of surgical oncology.

[12]  K. Soo,et al.  Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. , 2009, The Cochrane database of systematic reviews.

[13]  S. Fan,et al.  Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma , 2000, Cancer.